Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening
- PMID: 37096582
- PMCID: PMC11060750
- DOI: 10.1097/JU.0000000000003491
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening
Abstract
Purpose: The summary presented herein covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in the implementation of prostate cancer screening, biopsy, and follow-up. This is Part I of a two-part series that focuses on prostate cancer screening. Please refer to Part II for discussion of initial and repeat biopsies as well as biopsy technique.
Materials and methods: The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. The systematic review was based on searches in Ovid MEDLINE and Embase and Cochrane Database of Systematic Reviews (January 1, 2000-November 21, 2022). Searches were supplemented by reviewing reference lists of relevant articles.
Results: The Early Detection of Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance in prostate cancer screening, initial and repeat biopsy, and biopsy technique.
Conclusions: Prostate-specific antigen (PSA)-based prostate cancer screening in combination with shared decision-making (SDM) is recommended. Current data regarding risk from population-based cohorts provide a basis for longer screening intervals and tailored screening, and the use of available online risk calculators is encouraged.
Keywords: DRE; PSA; biopsy; early detection of prostate cancer; imaging; prostate cancer; prostate cancer screening; risk calculator; screening interval; shared decision-making.
Figures
Similar articles
-
Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy.J Urol. 2023 Jul;210(1):54-63. doi: 10.1097/JU.0000000000003492. Epub 2023 Apr 25. J Urol. 2023. PMID: 37096575 Free PMC article.
-
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.J Urol. 2024 Apr;211(4):509-517. doi: 10.1097/JU.0000000000003892. Epub 2024 Feb 29. J Urol. 2024. PMID: 38421253
-
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.J Urol. 2024 Apr;211(4):526-532. doi: 10.1097/JU.0000000000003890. Epub 2024 Feb 29. J Urol. 2024. PMID: 38421252
-
American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.BJU Int. 2013 Sep;112(5):543-7. doi: 10.1111/bju.12318. BJU Int. 2013. PMID: 23924423 Review.
-
Shared decision-making for prostate cancer screening and treatment: a systematic review of randomised controlled trials.Swiss Med Wkly. 2018 Feb 23;148:w14584. doi: 10.4414/smw.2018.14584. eCollection 2018. Swiss Med Wkly. 2018. PMID: 29473938 Review.
Cited by
-
A 5-Year Mortality Prediction Model for Prostate Cancer Patients Based on the Korean Nationwide Health Insurance Claims Database.J Pers Med. 2024 Oct 13;14(10):1058. doi: 10.3390/jpm14101058. J Pers Med. 2024. PMID: 39452565 Free PMC article.
-
A Working Framework to Address Diversity, Equity, and Inclusion in Undergraduate Medical Education.Med Sci Educ. 2024 May 28;34(5):1123-1131. doi: 10.1007/s40670-024-02065-1. eCollection 2024 Oct. Med Sci Educ. 2024. PMID: 39450040 Free PMC article.
-
Investigation on clinical risk factors of bladder lesion by machine learning based interpretable model.Sci Rep. 2024 Oct 16;14(1):24299. doi: 10.1038/s41598-024-75104-x. Sci Rep. 2024. PMID: 39414893 Free PMC article.
-
Identification of a 5-gene signature panel for the prediction of prostate cancer progression.Br J Cancer. 2024 Dec;131(11):1748-1761. doi: 10.1038/s41416-024-02854-w. Epub 2024 Oct 14. Br J Cancer. 2024. PMID: 39402324 Free PMC article.
-
Lifestyle and risk factors associated with elevated prostate-specific antigen levels in rural men: implications for health counseling.Front Oncol. 2024 Sep 23;14:1451941. doi: 10.3389/fonc.2024.1451941. eCollection 2024. Front Oncol. 2024. PMID: 39376990 Free PMC article.
References
-
- Siegel RL, Miller KD, Wagle NS et al.: Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17. - PubMed
-
- Mahal BA, Berman RA, Taplin ME et al.: Prostate cancer-specific mortality across gleason scores in black vs nonblack men. Jama 2018; 320: 2479. - PubMed
-
- Makarov DV, Chrouser K, Gore JL et al.: Aua white paper on implementation of shared decision making into urological practice. Urology Practice 2016; 3: 355. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
